The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.

The present invention relates to compounds of Formulas I-IV, which are salts of special lipid mediators of inflammation, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.

Antibiotic agents conjugated to a guanidinium-rich molecular transporter (GR-MoTr) are provided. The drug conjugates show surprising increases in efficacy compared to the unconjugated drug in difficult-to-treat bacterial infections including biofilms, stationary and persister cells, and multi-drug resistant bacteria, as well as intracellular bacteria.

The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.

The present invention relates to glucose-responsive hyaluronic acid nanoparticles having boronic acid compounds chemically bonded thereto, and a composition including the same. When the nanoparticles according to the present invention are used, cancer may be diagnosed and treated using a cancer cell-specific biological mechanism, without the use of existing contrast agents and anticancer agents which have the problem of toxicity.

Pharmaceutical formulations containing lipoic acid derivatives and ion pairs thereof are described. The pharmaceutical formulations are useful in the treatment of medical disorders, such as cancer.

The present invention relates to compounds of Formulas I-IV, which are salts of special lipid mediators of inflammation, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.

Polymer conjugates are provided that are capable of mimicking functions of natural proteoglycans found in the extracellular matrix of connective tissues. The polymer conjugates of the invention have utility in treating a subject suffering soft tissue degenerative conditions. Also provided are simple and scalable chemical processes for the preparation of the polymer conjugates of the invention.

The present invention provides a cationic lipid represented by the formula (I) ##STR00001##
wherein R.sup.1 and R.sup.2 each represents alkyl having 8 to 24 carbon atoms or the like; R.sup.3 represents a hydrogen atom, alkyl having 1 to 3 carbon atoms, the formula (A) ##STR00002##
wherein R.sup.4 and R.sup.5 each represents a hydrogen atom or the like, and n.sup.3 represents an integer from 2 to 6, or the formula (B) ##STR00003##
wherein R.sup.6 and R.sup.7 each represents a hydrogen atom or the like, and n.sup.4 represents an integer from 1 to 6; n.sup.1 represents an integer from 0 to 4; and n.sup.2 represents an integer from 1 to 4, provided that the case where n.sup.1 is 0 and n.sup.2 is 1 is excluded, and a composition which contains the cationic lipid and a nucleic acid, or the like.

Compositions of a modulator of cell metabolism, typically targeting cellular glycolysis, preferably with a targeting moiety, attached directly or indirectly to the inhibitor, or to a nanoparticle or other delivery vehicle thereof, and methods of use for treating cancer, proliferative disorders, neurodegenerative diseases, autoimmune disorders, or inflammatory diseases are provided. Pharmaceutical compositions including the targeted modulator and a pharmaceutically acceptable carrier are also provided. The pharmaceutical compositions can be administered to a subject in need thereof in an effective amount to reduce one or symptoms of the cancer, proliferative disorders, neurodegenerative diseases, autoimmune disorders, or inflammatory diseases alone or prior to or in conjunction with a further therapy such as radiotherapy.